Stockwatch: Lilly And GW Move Goalposts
This article was originally published in Scrip
Executive Summary
There were few bright spots last week in life sciences, with the NASDAQ Biotech Index finishing down by 4% as it continued, uncharacteristically, to underperform the broad S&P 500 index. The handful of positive announcements from the industry actually look very fragile on closer inspection, perhaps marking new lows for an industry where the integrity of clinical trial announcements and investment bank analysis can no longer be believed in.